Skip to main content
. 2019 May 24;38(2):468–477. doi: 10.1007/s10637-019-00787-3

Fig. 5.

Fig. 5

Time on treatment in a Stage 1; b Stage 2 ID, investigator’s decision; NSCLC, non-small-cell lung cancer; PD, progressive disease; SCLC, small-cell lung cancer; NC, non-compliant to the study treatment after being informed about discontinuation of navoximod development